Convalescent plasma therapy: A promising solution for SARS-CoV-2 outbreak

Anuj Kumar Singh\textsuperscript{a}, Animesh Chaterjee\textsuperscript{a}, Sandeep Sirohi\textsuperscript{a}, Nitin Sharma\textsuperscript{b} and Ashima Kathuria\textsuperscript{*\textsuperscript{a,}\textsuperscript{b}}

\textsuperscript{a}Department of Biotechnology, Meerut Institute of Engineering and Technology, Meerut, India
\textsuperscript{b}Department of Pharmaceutical Technology, Meerut Institute of Engineering & Technology, Meerut, India

Received 21 August 2020
Accepted 7 October 2020

Abstract. Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) has caused more than 18 million confirmed cases and 700000 deaths worldwide after the outbreak in November 2019 (COVID-19). It has been considered as most pathogenic infection under this category. Till date none of the therapeutics or prophylaxis measures have been claimed by any researcher which could cure the patient suffering from the SARS-CoV-2 infection. There is an urgent need for any alternative and effective way of disease management for COVID-19. However, convalescent plasma therapy (CPT) has gain attention of researchers with significant improvement of patient survival rate. Interestingly, there are numerous examples where CPT has proven its potential upon post-exposure prophylaxis and/or treatment in various diseases including COVID-19. This review summarizes the essential elements related to CPT, its past clinical evidences and application of CPT for the management of SARS-CoV-2 infection during COVID-19. We used the published literatures from PubMed, EMBASE and Medline databases until 31st May 2020.

Keywords: Convalescent plasma therapy, MERS, SARS-CoV-2, COVID-19

1. Introduction

The outbreak of novel coronavirus SARS-CoV-2 (nCoV) infection was associated with acute respiratory infection started in December 2019 from Wuhan city, Hubei province of China. Till 15 June 2020 the total number of 50, 54, 222 SARS-CoV-2 infected patients have been confirmed including 3, 02, 597 death globally [1]. Similar to past coronavirus outbreaks of SARS and Middle East respiratory syndrome (MERS), the nCoV also caused respiratory infection [2, 3]. Later it started crossing the boundaries of China and became a pandemic of the year 2019, named as COVID-19. Currently the COVID-19 has drawn a well deserved attention and became a global threat due to its spread in more than 200 countries, as reported by Worldometer (a private statistical data company). Zhou et al has discussed genomic comparison of SARS-CoV, MERS-CoV and novel SARS-CoV-2 with bat coronaviruses [4]. The study suggested that SARS-CoV-2 has long genome (~30 kb) and belong to \( \beta \) coronavirus type. However, the genome sequences were found 96% similar to bat coronavirus RaTG13 and 79% similar to SARS-CoV [4]. SARS-CoV-2 uses its S protein to interact with host receptor called “human angiotensin-converting enzyme 2 (hACE2)”, majorly present on lung epithelial cells. Binding affinity of the receptor-binding domain (RBD) of SARS-CoV-2, S protein is nearly 20-fold higher than that of SARS-CoV, causing higher infectivity and transmissibility of SARS-CoV-2 compared to SARS-CoV [5].

*Corresponding author: Dr. Ashima Kathuria, Department of Biotechnology, Meerut Institute of Engineering and Technology, Baghpat Crossing, Bypass Road, Meerut - 250005, U.P., India. Tel.:+91 0121 239439 /Ext. – 2055; E-mail: ashima.kathuria@miet.ac.in.
2. Convalescent plasma therapy (CPT)

Currently, the treatment options for nCoV through antiviral drugs are limited and the vaccines are still under clinical trials [6]. Thus Convalescent plasma therapy (CPT) is now considered as the best treatment option for critical patients since it has been successfully used in other viral disease outbreaks earlier [7, 8]. The possible mechanism of the CPT and its outcome in the pathogenesis of SARS-CoV-2 includes neutralizing antibodies (Nabs) response or direct neutralization of the virus (Fig. 1). Nabs of the transfused plasma can suppresses the viruses or helps in virus clearance [9]. In case of COVID-19, the peak of viraemia in a patient is prominent in the first week of infection and the primary immune response of the host generally develops from day 10 to day 14 from the infection [10]. Thus administration of convalescent plasma would be more effective if administered at the early stage of the disease but currently it is not possible due to the treatment guideline provided by FDA [11]. However, the efficacy of CPT depends on the concentration of the NAb in plasma from recovered donors. It was discovered that Nabs plays a role by binding to the spike proteins of the coronavirus, and hence inhibiting viral entry and replication [12]. Moreover, CP also helps in control of overactive immune response by providing passive immunomodulatory effect which helps the recipient to control the excessive inflammatory cascade induced by COVID-19 [13].

3. Significance of CPT in past pandemics

The therapy has been used since it was first adopted in 1918-1920 for Spanish flu and proven its importance in many viral pandemics like Ebola, MERS as well as other SARS associated outbreaks [40–43]. However it was first tested in diphtheria, a bacterial disease, in late 1890 for which Emil Behring was awarded Novel prize in 1901. The COID-19 pandemic necessitates the step towards the
CPT until there is no proper medicine or vaccine available sufficiently. The evidences for past success of the plasma therapy are listed in Table 1.

### 4. Regulatory aspects of CPT

Recently FDA expedites the process of clinical trial approval through e-filling. FDA released a set of guidelines for CPT which majorly covers the route to start the investigation in US, fixed the eligibility criteria of patient recruitment, collection of plasma from the eligible donors with proper labelling and maintenance of record [36]. According to these guidelines, investigator should submit application under the traditional IND regulatory pathway.

In continuation, the ICMR also released their guidelines and approved 34 clinical trials recently for CPT [31]. Since, China was the first country to report COVID-19 they started clinical trials for every possible treatment options including CPT. Currently, most of the clinical studies for any COVID-19 research are from China or the prior affected countries like Korea and Italy.

### 5. Application of convalescent plasma therapy (CPT) in COVID-19

The CPT is based on the passive immunity (or antibody) developed among the recovered patient. The therapy is among one of the major option during COVID-19 pandemic [32]. However, the significance of the therapy has not been clinically proven. Since there are no vaccines or antibodies available for the treatment of SARS-CoV-2 patients’ CPT has proven its efficacy at significant level [39]. Recently CPT was adopted for the treatment of hepatitis E virus infection in an immunocompromised elderly
patient [44]. Although some studies has been published before FDA guidelines for the convalescent plasma for investigators and healthcare professionals [44].

6. Clinical practices

Currently, the clinical evidences for the solicitation of CPT belong to China and Korea. In addition, a letter to the editor was submitted by an Italian team Franchini et al to suggest how CP should be collected from a recovered patients [45]. Till date there are seven reports on CPT where the studies were done with a very small sample size and critical patients (Table 2). Since the CPT was adopted after realizing that the patient’s condition did not improve with the all available treatment options. Among the described reports, one study showed 5 patients died out of 6 after receiving the CPT but the result was similar to other successful studies in terms of clearing the viral loads in all 6 patients [36]. Here the test subjects in the study received the CP after ~21.5 days of virus detection and critically damaged respiratory system. Overall the study emphasizes that CP must be provided within 14 days of infection [37]. In all the studies, before the CP transfusion ABO compatibility and confirmatory tests for other viral infections such as HIV, Syphilis, HBV and HCV were precarious [36–39]. However, single 200–250 ml dose were effectively cleared the viral load from patients but in some cases the number of doses were increased up to 8 in order to cure the critical patients [37, 40, 41]. In another study, the CPT was found effective in 5 critical patients with two doses of ~200 to 250 ml and the other life

<table>
<thead>
<tr>
<th>Sl. No.</th>
<th>Location of study</th>
<th>No. of patients’ CP (ml)</th>
<th>Dose of CP (ml)</th>
<th>Additional drug &amp; support</th>
<th>Effect of CPT</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Wuhan, China</td>
<td>10</td>
<td>200</td>
<td>Antiviral therapy and other life support</td>
<td>No death, 7 improved, 3 discharged</td>
<td>[38]</td>
</tr>
<tr>
<td>2.</td>
<td>Nanjing, China</td>
<td>1</td>
<td>200</td>
<td>Invasive mechanical ventilation</td>
<td>No ventilation needed after 11 days of transfusion (improved)</td>
<td>[45]</td>
</tr>
<tr>
<td>3.</td>
<td>Wuhan, China</td>
<td>6</td>
<td>200 (1 to 3 time)</td>
<td>No information</td>
<td>All patients’ showed radiological and symptomatic improvement</td>
<td>[37]</td>
</tr>
<tr>
<td>4.</td>
<td>Zhengzhou, China</td>
<td>6</td>
<td>300 (3 times)</td>
<td>ICU + other</td>
<td>Virus cleared in all patients, 5 died &amp; 1 survived</td>
<td>[44]</td>
</tr>
<tr>
<td>5.</td>
<td>Guangdong, China</td>
<td>4</td>
<td>200 to 400 (1 to 8 doses)</td>
<td>ICU + other</td>
<td>All 4 recovered</td>
<td>[40]</td>
</tr>
<tr>
<td>6.</td>
<td>Seoul, Korea</td>
<td>2</td>
<td>250 (2 doses)</td>
<td>Hydroxychloroquine, lopinavir/ritonavir &amp; other life support</td>
<td>Both patients recovered</td>
<td>[41]</td>
</tr>
<tr>
<td>7.</td>
<td>Shenzhen, China</td>
<td>5</td>
<td>400 mL(Total)</td>
<td>Mechanical ventilation + antiviral agents</td>
<td>All five recovered</td>
<td>[39]</td>
</tr>
</tbody>
</table>
support with antiviral drugs [42]. The improved medical conditions of the recipients were observed through the increased leucocytes ($0.65 \times 10^9 \rightarrow 0.75 \times 10^9$ per L), decrease in C-protein level (55.98 $\rightarrow 18.13$ mg/L), increased oxyhemoglobin saturation (93% $\rightarrow 96$%) apart from the fever, cough and other common symptoms [38]. In addition, the chest CT scan was the major concern which was associated with the patients’ respiratory issues such as shortness of breath, chest pain and abnormal ground-glass opacity (GGO) of the nCoV-2 infected person [37, 40, 41]. Interestingly, the improved CT report was observed in most of the cases after CP transfusion except the Zeng Q-L et al. case study [38, 43, 44].

Recently, in a study the characterization and analysis of the CP donor was done where the team emphasize on donor rather than recipients [45]. However most of the studies were checked for donors IgM and IgG titer, confirmation of negative result of severe viral disease including nCoV-2, HIV, HBV etc. as well as respiratory issues [38, 41, 44]. In the study of Zhang L et al. included C-reactive protein, IL-6, CD3/CD4, creatine kinase and lactate dehydrogenase level apart from the above. It helped the CP recipient to be provided additional care if accepting abnormal plasma [45].

7. Conclusion

Convalescent plasma therapy has been useful in treatment of many infectious diseases, including viral infections. However, very few clinical evidences are available so far related to its application in SARS-CoV-2 treatment but all reports are in support that the therapy can be effectively used. In the situation where there are no available drugs and vaccines, convalescent plasma therapy have shown potent application in the treatment of -SARS-CoV-2 infections. For more evidence and data, large multi-centric clinical study should be performed.

Conflict of interest

The authors have no conflict of interest to report.

References


